Pharvaris (PHVS) News Today $21.65 -1.19 (-5.21%) Closing price 04:00 PM EasternExtended Trading$21.66 +0.01 (+0.02%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHVS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Pharvaris N.V. (NASDAQ:PHVS) Receives $35.60 Consensus PT from BrokeragesAugust 28 at 2:09 AM | americanbankingnews.comPharvaris (NASDAQ:PHVS) Stock Price Up 5.9% - What's Next?August 27 at 1:20 PM | marketbeat.comPharvaris N.V. (NASDAQ:PHVS) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesAugust 27 at 3:21 AM | marketbeat.comPharvaris (NASDAQ:PHVS) Upgraded to Hold at Zacks ResearchAugust 22, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Shares Up 6.2% - Here's What HappenedAugust 21, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Upgraded at Zacks ResearchAugust 21, 2025 | americanbankingnews.comPharvaris N.V. (NASDAQ:PHVS) Short Interest UpdateAugust 20, 2025 | marketbeat.comPharvaris Advances Clinical Pipeline with Strong FinancialsAugust 20, 2025 | msn.comWhat is Leerink Partnrs' Estimate for Pharvaris Q3 Earnings?August 19, 2025 | marketbeat.comQ3 Earnings Estimate for Pharvaris Issued By Leerink PartnrsAugust 19, 2025 | americanbankingnews.comCantor Fitzgerald Increases Earnings Estimates for PharvarisAugust 17, 2025 | marketbeat.comWedbush Comments on Pharvaris' Q3 Earnings (NASDAQ:PHVS)August 17, 2025 | marketbeat.comWedbush Predicts Pharvaris' FY2029 Earnings (NASDAQ:PHVS)August 16, 2025 | marketbeat.comJMP Securities Lowers Pharvaris (NASDAQ:PHVS) Price Target to $52.00August 15, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Posts Quarterly Earnings Results, Misses Expectations By $0.07 EPSAugust 14, 2025 | marketbeat.comPharvaris price target lowered to $52 from $55 at Citizens JMPAugust 13, 2025 | msn.comPharvaris Reports Q2 2025 Financials and Advances Phase 3 StudiesAugust 12, 2025 | msn.comPharvaris Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 12, 2025 | globenewswire.comPharvaris (PHVS) Projected to Post Earnings on WednesdayAugust 6, 2025 | marketbeat.comTD Asset Management Inc Has $1.23 Million Holdings in Pharvaris N.V. (NASDAQ:PHVS)August 4, 2025 | marketbeat.comPharvaris N.V. (NASDAQ:PHVS) Given Consensus Recommendation of "Buy" by BrokeragesJuly 31, 2025 | marketbeat.comPharvaris N.V.'s (NASDAQ:PHVS) 11% loss last week hit both individual investors who own 37% as well as institutionsJuly 27, 2025 | finance.yahoo.comPharvaris (NASDAQ:PHVS) Sees Large Volume Increase - Here's What HappenedJuly 26, 2025 | marketbeat.comPharvaris shares slide following $175 million equity offeringJuly 25, 2025 | msn.comPharvaris Raises $201 Million in Successful OfferingJuly 24, 2025 | tipranks.comPharvaris (NASDAQ:PHVS) Shares Gap Down - Here's What HappenedJuly 24, 2025 | marketbeat.comPharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsJuly 22, 2025 | globenewswire.comPharvaris Announces Proposed Public Offering of Ordinary SharesJuly 22, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (ARCT) and Pharvaris (PHVS)July 17, 2025 | theglobeandmail.comPharvaris (NASDAQ:PHVS) Stock Price Down 5.9% - Here's What HappenedJuly 15, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume - Time to Buy?July 14, 2025 | marketbeat.comBank of America Securities Reaffirms Their Sell Rating on Pharvaris (PHVS)July 12, 2025 | theglobeandmail.comPharvaris (NASDAQ:PHVS) Reaches New 1-Year High - Here's What HappenedJuly 12, 2025 | marketbeat.comPharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 ...July 11, 2025 | morningstar.comMPharvaris (NASDAQ:PHVS) Stock Price Up 9.9% - Time to Buy?July 11, 2025 | marketbeat.comPharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025July 10, 2025 | globenewswire.comPharvaris N.V. (NASDAQ:PHVS) Receives Consensus Rating of "Buy" from BrokeragesJuly 6, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Shares Gap Up - What's Next?July 3, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Trading Down 4.9% - What's Next?June 27, 2025 | marketbeat.comPharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National SummitJune 27, 2025 | globenewswire.comPharvaris N.V. (9EN.F) stock price, news, quote & history - Yahoo FinanceJune 26, 2025 | sg.finance.yahoo.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (BMY) and Pharvaris (PHVS)June 24, 2025 | theglobeandmail.comPharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat ...June 16, 2025 | gurufocus.comPharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat ...June 16, 2025 | gurufocus.comPharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI CongressJune 16, 2025 | globenewswire.comPharvaris (NASDAQ:PHVS) Given Average Rating of "Buy" by BrokeragesJune 11, 2025 | marketbeat.comCantor Fitzgerald Predicts Pharvaris FY2026 EarningsJune 11, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Now Covered by Analysts at GuggenheimJune 11, 2025 | marketbeat.comBank of America Corp DE Increases Stake in Pharvaris (NASDAQ:PHVS)June 11, 2025 | marketbeat.comPharvaris Announces 2025 Annual Shareholders Meeting Amidst Phase 3 TrialsJune 10, 2025 | tipranks.com Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PHVS Media Mentions By Week PHVS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PHVS News Sentiment▼0.911.04▲Average Medical News Sentiment PHVS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PHVS Articles This Week▼43▲PHVS Articles Average Week Get the Latest News and Ratings for PHVS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Pharvaris and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies TG Therapeutics News Cytokinetics News Ascentage Pharma Group International News Krystal Biotech News ACADIA Pharmaceuticals News ADMA Biologics News Telix Pharmaceuticals News Vaxcyte News PTC Therapeutics News Lantheus News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PHVS) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharvaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access